For more than 100 years, FarmaMondo has provided thousands of caregivers globally with access to pharmaceuticals that are commercially unavailable in their home countries.
We offer cohorts access to established products that are not commercial available in some countries. We address unmet patient needs around the world by deploying our robust distribution infrastructure and navigating through the complex regulatory environments for the supply of unlicensed medicines (ULMs).
FarmaMondo’s business services for access to unlicensed medicines cover:
SHORTAGES OF ESTABLISHED PRODUCTS
Medicine shortages are a growing and complex global challenge. Shortages of essential drugs are becoming increasingly frequent globally, burdening health systems with additional costs and posing risks to the health of patients who fail to receive the medicines they need. More than 85% of EU hospitals report medicine shortages as an acute problem. Commonly prescribed hospital medicines undergoing shortages have significant negative impacts on patient’s care. A hospital, facing medicine shortages without having a locally-available licensed- replacement therapy, can only find a solution by utilizing unlicensed medicine routes to source and import an alternative treatment commercially available in another country. FarmaMondo serves HealthCare Providers (or Medical Providor/Personal) globally with safe and uninterrupted supply of alternative to those on shortage products.
Being a preferred provider of Unlicensed Medicines to thousands of HCPs globally seeking ethical access to yet commercially unavailable therapies in their markets, the Group’s network and geographical footprint supports wider access options for the Biopharma.
MARKET EXIT AND PRODUCT SUPPLY DISCONTINUATION
The market exit of a drug is a valid strategic direction for biopharmaceutical companies, but discontinuing a therapy could potentially result in an unmet medical need for patients who are unable to find suitable replacement therapies. The solution for pharmaceutical manufacturers wanting to reduce the impact on patients is to put in place a managed access programme allowing patients to have access to the required medicine beyond product discontinuation on an unlicensed basis.